Pacific Biosciences is trading at $2.79, up 13.80% on October 28, 2026, as biotech-sector strength may be supporting the advance.
- No new company-specific announcement explaining the move was identified; its latest listed release is the October 19 Verily collaboration.
- The supplied sector context says XBI is up 2.18%, amid positive clinical-trial and regulatory news.
- Earlier company developments and positioning ahead of the upcoming quarterly report are background, not a confirmed catalyst for this morning’s move.